Market Overview

Impax Labs Enters Commercialization Deal with Perrigo

Related PRGO
25 Stocks Moving In Wednesday's Pre-Market Session
David Einhorn's Letter To Greenlight Investors Reveals New Perrigo Position
Related IPXL
Turing Rejects $100 Million Offer For Daraprim
Vetr Crowd Urges Sell For Impax Laboratories

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Perrigo Company (NASDAQ: PRGO;TASE) on the development, manufacturing and commercialization of an extended topical generic drug product with first to market potential. The product and terms of the agreement were not disclosed.

Posted-In: News


Related Articles (IPXL + PRGO)

View Comments and Join the Discussion!